<p style="font-weight: 400;">On Thursday, the U.S. Food and Drug Administration (FDA) <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-novel-non-opioid-treatment-moderate-severe-acute-pain">approved</a> Journavx (suzetrigine) 50 mg oral tablets, a first-in-class non-opioid analgesic for the treatment of moderate to severe acute pain in adults.</p>
<p style="font-weight: 400;">Developed by Vertex Pharmaceuticals, Journavx represents a novel approach to pain management, targeting sodium channels in the peripheral nervous system to block pain signals before they reach the brain, offering an alternative to addictive opioids for post-surgical pain.</p>
<p style="font-weight: 400;" data-path-to-node="1">The FDA highlighted this approval as a major public health milestone, providing patients with a safer pain management option while addressing the opioid crisis. The agency has long promoted the development of non-opioid therapies through its Overdose Prevention Framework, issuing guidance to encourage innovative analgesics and supporting clinical practice guidelines for acute pain management. Journavx’s application received Breakthrough Therapy, Fast Track, and Priority Review designations, reflecting its therapeutic significance.</p>
<p style="font-weight: 400;" data-path-to-node="2">Efficacy was demonstrated in two randomized, double-blind, placebo- and active-controlled clinical trials involving patients recovering from abdominoplasty and bunionectomy. Both trials showed that Journavx significantly reduced pain compared to placebo, with participants allowed to use ibuprofen as “rescue” medication if needed. Safety data from 874 participants in these trials, along with supportive data from 256 patients in a separate open-label study, showed that common adverse effects included itching, muscle spasms, rash, and elevated creatine phosphokinase. Journavx is contraindicated with strong CYP3A inhibitors and should not be taken with grapefruit-containing foods or drinks.</p>
<p style="font-weight: 400;" data-path-to-node="3">Journavx joins the broader category of non-opioid analgesics, which includes acetaminophen, NSAIDs, COX-2 inhibitors, topical agents, and adjuvant therapies. Unlike opioids, these drugs relieve pain without binding to central opioid receptors, avoiding risks of dependence, tolerance, and respiratory depression. Journavx distinguishes itself as the first approved drug to block pain at peripheral nerves without affecting the brain, offering a promising new option for acute pain management while reducing reliance on opioid medications.</p>
<p style="font-weight: 400;">Most side effects in clinical trials were rated as mild to moderate and resolved without long-term issues. While no serious adverse events were directly linked to the drug in primary trials, the FDA and medical guides list several precautions:</p>
<ul style="font-weight: 400;">
<li>Liver Function: Patients with moderate hepatic impairment require a lower dose. The drug is not recommended for those with severe liver disease (Child-Pugh Class C).</li>
<li>Kidney Function: It should be avoided in patients with severe renal impairment (eGFR &lt;15 mL/min).</li>
<li>Fertility &amp; Pregnancy: It may temporarily reduce the chance of becoming pregnant while on treatment. There is currently no human data on its safety during pregnancy or breastfeeding.</li>
</ul>

<script async src="https://www.instagram.com/embed.js"></script>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
<script async src="https://www.tiktok.com/embed.js"></script><div data-widget-host="revcontent" data-pub-id="165152" data-widget-id="290588"></div><script src="https://delivery.revcontent.com/165152/290588/widget.js"></script>

Breakthrough In Acute Pain Management: FDA Approves First-In-Class Non-Opioid

CONTINUE READING

Fetterman Says There’s One Thing Trump Can’t Afford To Do On Iran

The Chilling Six Seconds Before A Great-Grandmother Was Butchered On A Train

Bernie Sanders Wants To Cripple America’s AI Advantage

Man Vs. Machine: Red State Slaps OpenAI With Monster Lawsuit

Trump Taps Familiar Name To Replace Tulsi Gabbard

‘Cosplaying Working Class’: Dem Strategist Highlights Party’s Big Graham Platner Problem

News

Big Pharma

Health

Pharmaceuticals

U.S.

A video goes viral showing a baby being refused his mother by two gay "dads". This is just the tip of the iceberg, which is why we will have an important discussion today about surrogacy. 

Hour 1

The Matt Walsh Show

Ep. 1765 - This Video Is One Of The Worst Things I've Seen In A Long Time 

The Strait of Hormuz officially opens for business (kind of), the Pope makes “shocking” comments on immigration, and President Trump promises UFO disclosure at TPUSA. 


The Michael Knowles Show

Ep. 1956 -  Pope Leo's "SHOCKING" Immigration Comments EXPLAINED

A false miscreed has corrupted our leadership class.


The Andrew Klavan Show

Ep. 1275 - Dumb, Dumber and Progressive

President Trump announces a 10-day ceasefire between Lebanon and Israel, a murder-suicide involving former Democratic Lieutenant Governor Justin Fairfax shakes Virginia, and France and Britain hold a conference to secure the Strait of Hormuz – after the Iranian conflict ends. Get the facts first with Morning Wire.

- - -

Ep. 2738

- - -

Wake up with new Morning Wire merch: https://bit.ly/4lIubt3

- - -

Today's Sponsors:

Alliance Defending Freedom - Visit https://JoinADF.com/WIRE or text 'WIRE' to 83848 to learn more.

Pocket Hose - Text MORNING to 64000 to get a FREE pocket pivot and their 10-pattern sprayer with the purchase of ANY size Copper Head hose. Message and data rates may apply.

Morning Wire

U.S. Expands Hormuz Blockade & VA Fairfax Deaths Investigated | 4.17.26

U.S. Expands Hormuz Blockade & VA Fairfax Deaths Investigated | 4.17.26 [Member Exclusive]

A ceasefire goes into effect between Israel and Lebanon, a tragic murder-suicide rocks Virginia, and Dairy Queen deploys AI in the drive-thru. Get the facts first with Evening Wire.
- - -
Ep. 2737
- - -
Wake up with new Morning Wire merch: https://bit.ly/4lIubt3 
- - -
Today’s Sponsor:

Alliance Defending Freedom - Visit https://JoinADF.com/WIRE or text “WIRE” to 83848 to learn more.


Evening Wire: Lebanon Ceasefire Begins & Murder-Suicide Rocks VA | 4.16.26

The Pendragon Cycle

Menu

— News —

Breakthrough In Acute Pain Management: FDA Approves First-In-Class Non-Opioid